Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05130047 · ClinicalTrials.gov registry record · Phase 2
Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
A Phase 2 study, sponsored by Michael Camilleri, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT05130047: Completed Phase 2 study, sponsored by Michael Camilleri, MD.
NCT05130047 is a Phase 2 study that has completed, run by Michael Camilleri, MD. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05130047, a Phase 2 study, has completed, sponsored by Michael Camilleri, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This single-center, randomized, double-blind, placebo-controlled study is designed to compare effects of aldafermin, (NGM282), 1 mg, and placebo given daily by subcutaneous injection on bowel functions and hepatic synthesis and fecal excretion of bile acids in patients with diarrhea associated with bile acid malabsorption (BAM).
Primary Outcome
Fasting serum C4 is measured by liquid chromatography-mass spectrometry.
Interventions
- DRUG Placebo
- DRUG Aldafermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2022-11-08 |
| Phase | Phase 2 |
What the finished NCT05130047 record still lists
NCT05130047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05130047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05130047 about?
NCT05130047 is a clinical study titled "Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)". This single-center, randomized, double-blind, placebo-controlled study is designed to compare effects of aldafermin, (NGM282), 1 mg, and placebo given daily by subcutaneous injection on bowel functions and hepatic synthesis and fecal excretion of bile acids in patients with diarrhea associated with ...
What is the current status of trial NCT05130047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-12-01. Estimated completion is 2022-11-08.
What interventions are being tested in trial NCT05130047?
The interventions under investigation include: Placebo (DRUG), Aldafermin (DRUG).
Who is sponsoring clinical trial NCT05130047?
This trial is sponsored by Michael Camilleri, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05130047's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI